Drugs / CD146-directed CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07067255 | Apr 2025 → Dec 2028 expected | ovarian carcinoma, ovarian sarcoma | Essen Biotech | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD146-directed CAR-T cells | “Eligible patients will undergo lymphodepleting chemotherapy with cyclophosphamide and fludarabine, followed by an infusion of autologous CD146-directed CAR-T cells (Arm A) and...” NCT07067255 ↗ |
| Modality | Cell therapy | “CD146-targeted and GPC3-targeted CAR-T cell therapy” NCT07067255 ↗ |
| Route | Intravenous | “IV administration of investigational therapy, GPC3/CD146 CAR T cells, over 10-20 minutes on day 0.” NCT07067255 ↗ |
| Target | MCAM | “CD146 (also known as MUC18 or MCAM) is a cell adhesion molecule involved in tumor angiogenesis and metastasis; it is frequently overexpressed in ovarian cancer and has been...” NCT07067255 ↗ |